📰 Genentech News
Page 229 - Genentech News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Genentech. Real-time updates on events, politics, business and more.
December 7, 2022
/PRNewswire/ - CAR T Global Consultant Inc. - a specialized cell therapy consulting company and Titronbio (TM) - a company specialized in Cell and Gene therapy...
December 7, 2022
Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the neoadjuvant setting had an overall response rate of 75 percent in the absence of anastrozole and 63 percent in combination with anastrozole, according to results from the phase II TRIO-US B-12 TALENT trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.
December 7, 2022
Genentech has voluntarily withdrawn the US indication for Tecentriq (atezolizumab) for previously untreated urothelial carcinoma.
December 7, 2022
/PRNewswire/ - CAR T Global Consultant Inc. - a specialized cell therapy consulting company and Titronbio (TM) - a company specialized in Cell and Gene therapy...
December 7, 2022
The emerging science of phenomics could shift the focus of health care from treating the sick to the prediction and prevention of disease.
December 6, 2022
Complex, Customized CRISPR Combo Could Help Patients Cure Their Own Cancer - “In a small phase 1 clinical trial run by PACT Pharma, researchers edited the genes of 16...
December 6, 2022
In a letter to faculty, Stanford University president Marc Tessier-Lavigne on Monday addressed the allegations that surfaced last week regarding research misconduct in scientific papers he co-authored. “Three papers being questioned are ones on which I am the senior author: a 1999 Cell paper, and two papers published in Science in 2001. I previously corresponded extensively
December 6, 2022
Genentech has voluntarily withdrawn the US indication for Tecentriq (atezolizumab) for previously untreated urothelial carcinoma.
December 6, 2022
On this episode of Dimensions of Diversity, host Lloyd Freeman speaks with Jayson Johnson, Head of D&I Business Partnering and Learning & Development. The COVID-19 pandemic shined...
December 6, 2022
The Food and Drug Administration relies on preliminary data to make the decision, but asks companies to conduct follow-up studies to confirm that the drug works.